Catalent, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTLT research report →
Range $41 – $132
Price Chart
About the company
Catalent, Inc. , operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services.
- CEO
- Alessandro Maselli
- IPO
- 2014
- Employees
- 17,000
- HQ
- Somerset, NJ, US
Get TickerSpark's AI analysis on CTLT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.52B
- P/E
- -11.02
- Fwd P/E
- 26.56
- PEG
- -0.32
- P/S
- 2.63
- P/B
- 3.19
- EV/EBITDA
- -57.12
- Div Yield
- 0.00%
- Gross Margin
- 21.75%
- Op Margin
- -17.10%
- Net Margin
- -23.81%
- ROE
- -25.32%
- ROIC
- -8.53%
Latest fiscal year · YoY change
- Revenue
- $4.38B+2.5%
- Gross Profit
- $953.00M-10.1%
- Op Income
- $-749,000,000
- Net Income
- $-1,043,000,000-349.6%
- EPS
- $-5.76-350.0%
- OCF Growth
- +2.7%
- FCF Growth
- +81.7%
- 52W High
- $63.50
- 52W Low
- $42.11
- 50D MA
- $60.41
- 200D MA
- $58.22
- Beta
- 1.16
- RSI (14)
- 74
- Avg Volume
- 2.27M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Catalent delivered a softer reported quarter on COVID decline and lower margins, but reaffirmed full-year guidance and pointed to improving cash flow, Biologics execution, and GLP-1/gene therapy growth as the main upside drivers.· November 15, 2023
- Q1 revenue was $982 million, down 4% reported and 6% constant currency, mainly because COVID revenue fell by about $85 million and a prior-year $30 million licensing fee rolled off.
- Adjusted EBITDA fell 38% to $115 million, with margin at 11.7% versus 18.3% a year ago; adjusted net loss was $19 million, or $0.10 per diluted share.
- Biologics showed sequential improvement: EBITDA rose to $52 million from a $12 million loss in Q4, and margin improved 1,400 bps sequentially to 11.6%.
- Management reaffirmed FY24 guidance: revenue of $4.3 billion to $4.5 billion, adjusted EBITDA of $680 million to $760 million, and adjusted net income of $113 million to $175 million.
- Free cash flow outlook improved to more than $100 million for FY24, versus the prior expectation of neutral, as contract assets are expected to decline.
Catalent reported preliminary Q1 FY24 net revenue of $982 million, down 4% reported and 6% constant currency versus the prior-year quarter. Adjusted EBITDA was $115 million, down 38%, with margin of 11.7% versus 18.3% last year. Adjusted net loss was $19 million, or $0.10 per diluted share, versus adjusted net income of $61 million, or $0.34 per diluted share a year ago. By segment, Biologics revenue was $447 million, down 16%, with EBITDA of $52 million and margin of 11.6%; Pharma and Consumer Health revenue was $535 million, up 5%, with EBITDA of $101 million and margin of 18.9%. For FY24, management reiterated revenue guidance of $4.3 billion to $4.5 billion, adjusted EBITDA of $680 million to $760 million, adjusted net income of $113 million to $175 million, COVID revenue of about $180 million, and CapEx of about $400 million, or 8% to 10% of revenue. Free cash flow is now expected to be above $100 million, versus an earlier neutral outlook.
Alessandro Maselli said the company delivered a strong start to FY24 despite macro headwinds and is seeing operational improvement across Biologics, including a 1,400 basis-point sequential EBITDA margin rebound. He highlighted healthy gene therapy demand, growing GLP-1 exposure, and a new consumer health gummy contract as evidence that the pipeline is converting into growth. His tone was confident but measured: he repeatedly stressed prudent planning, capacity ramping, and not assuming everything goes right in the model.
Matti Masanovich emphasized the financial cleanup and closing-process issues, including a roughly $700 million non-cash goodwill impairment assumed in preliminary results and delayed 10-K/10-Q filings expected by Nov. 27 and shortly after. He said the balance sheet remains flexible, with the nearest debt maturity in 2027, net first-lien leverage at 3.4x versus a 6.5x covenant, and overall net leverage at 7.4x due to lower LTM EBITDA. He also highlighted $209 million of cash, $543 million of contract assets, Q1 CapEx of $84 million, and a stronger cash profile ahead as contract assets are reduced and free cash flow rises above $100 million.
Analysts focused on Sarepta/ELEVIDYS upside and downside, GLP-1 capacity ramp timing, concentration risk, and whether the strategic review was taking longer than expected. Management said Sarepta demand remains firm, production is booked on a rolling six-month basis, and about 90% of Sarepta revenue is tied to ELEVIDYS, but they would not speculate on FDA label expansion. On GLP-1s, management said FY24 revenue is below $100 million, that demand is strong, and that capacity—not demand—is the current constraint. On the strategic review, John Greisch said the Board is now past the “crisis mode” phase and is evaluating options deliberately with Elliott, but no decisions were announced.
The bull case from the call is that Catalent is exiting the worst of the operational drag and is starting to show better execution, especially in Biologics, where margins improved sharply sequentially. Management also sounded increasingly constructive on GLP-1s, gene therapy, and consumer health wins, while free cash flow guidance improved materially and contract assets are expected to unwind. The company reiterated full-year targets, suggesting confidence that second-half growth and margin recovery are still on track.
The bear case is that reported results still reflect heavy COVID decline, margin compression, and a large goodwill impairment tied to past acquisitions. There is also meaningful customer concentration, with one strategic customer representing 30% of aggregate net trade receivables and contract assets and about 16% of Q1 revenue, while the Sarepta/ELEVIDYS relationship remains a major swing factor. Investors also have to contend with delayed SEC filings, underutilized capacity in some newer facilities, and uncertainty around how quickly GLP-1 and gene therapy opportunities can fully offset legacy weakness.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.4%
- Shares Outstanding
- 181.51M
- Float Shares
- 180.36M
of shares held by institutions
500 13F filers
Buy/sell ratio 0.49. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CTLT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Nov 15, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | May 23, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | May 19, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 25, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Buy | Mar 7, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Mar 24, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 14, 23 | Filing → |
| Susie LeeHouse · NV03 | Sell | Nov 30, 22 | Filing → |
| Kurt SchraderHouse · OR05 | Sell | Nov 12, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Nov 3, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | May 23, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 5, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Feb 17, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 20, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 15.35M | ▲ 157.68K |
| Segantii Capital Management Ltd | 250.00K | ▲ 250.00K |
| Credit Suisse AG/ | 210.04K | ▼ 118.27K |
| Eisler Capital (Uk) Ltd. | 165.32K | ▲ 165.32K |
| Flow State Investments, L.P. | 30.00K | ▲ 30.00K |
| Fjarde Ap-Fonden (The Fourth Swedish National Pensionfund) | 26.90K | ▲ 26.90K |
| Dfpg Investments, LLC | 18.25K | ▲ 2.52K |
| Cetera Advisor Networks LLC | 10.46K | ▲ 10.46K |
| Eisler Capital (Us) LLC | 10.00K | ▲ 10.00K |
| Cowen And Company, LLC | 6.29K | ▲ 6.29K |
| Raymond James Financial Services Advisors, Inc. | 5.22K | ▼ 3.51K |
| Raymond James & Associates | 4.92K | ▲ 4.92K |
Held by 17 ETFs
Biggest fund positions in CTLT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 18, 24 | Gennadios Aristippos | other | 21,562 |
| Dec 18, 24 | Gennadios Aristippos | sell | 21,562 |
| Dec 18, 24 | McErlane David | other | 11,426 |
| Dec 18, 24 | McErlane David | sell | 14,740 |
| Dec 18, 24 | McErlane David | sell | 11,426 |
| Dec 18, 24 | Hatzfeld Michael | other | 3,144 |
| Dec 18, 24 | Hatzfeld Michael | sell | 3,144 |
| Dec 18, 24 | Gunther Scott | other | 12,938 |
| Dec 18, 24 | Gunther Scott | sell | 12,938 |
| Dec 18, 24 | Ferraro Joseph Anthony | other | 14,265 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTLT coverage
Recent articles, reports, and earnings notes.
Want a deeper read on CTLT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio
businesswire.com · Oct 12
Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
reuters.com · Aug 7
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
globenewswire.com · Aug 3
Catalent Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services
businesswire.com · Jun 16
Cartherics and Catalent Expand Commercial License Agreement
businesswire.com · Apr 9
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
businesswire.com · Mar 11
SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs
businesswire.com · Jan 12
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
globenewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
